BD (Becton, Dickinson and Company) announced today that Fresenius Kabi USA has acquired the BD Rx business, which includes a pharmaceutical manufacturing plant in Wilson, N.C., and the BD Simplist™ line of seven drugs in ready-to-administer prefilled glass syringes.
BD and Fresenius Kabi have also signed a 10-year supply and distribution agreement under which Fresenius Kabi will supply BD with a portfolio of intravenous solutions. Both BD and Fresenius Kabi plan to offer a range of IV solutions in the U.S. beginning in 2016.
BD will record an asset write-off related to the sale, which is expected to be immaterial to the Company’s fiscal 2016 results. Excluding the write-off, the Company expects the divestiture of BD Rx to be modestly accretive to fiscal 2016 adjusted diluted earnings per share. Additional financial and contractual terms of the transactions were not disclosed.